Detailed Narrative
IPO and Strategic Growth Initiatives
GEM Aromatics successfully listed on NSE and BSE on August 26, 2025, marking a significant milestone in its 27-year journey. The IPO was undertaken to strengthen the balance sheet by partially repaying borrowings and supporting long-term growth plans. The company is transitioning from a single-product, single-facility setup to a leading specialty ingredient company, now offering 70 products and serving over 269 customers across 18 countries.
Q2 FY26 Financial Performance Overview
For Q2 FY26, GEM Aromatics reported revenue from operations of ₹89.5 crores. EBITDA stood at ₹3 crores, resulting in an EBITDA margin of 3.4%, and the company recorded a net loss of ₹2.6 crores. For the first half of FY26, revenue was ₹177.2 crores, with EBITDA at ₹17.9 crores (10.1% margin) and a net profit of ₹5.4 crores (3.1% margin). Depreciation increased to ₹4.8 crores in H1 FY26 from ₹3.5 crores in H1 FY25, impacting overall profitability.
Dahej Plant Commissioning and Capacity Expansion
The Phase-II of the new Dahej plant, part of Krystal Ingredients, is expected to commence production on November 30, 2025. This facility, representing an investment of ₹250 crores funded by internal accruals and debt, will add 10,829 metric tons of new capacity. It will house India's largest Cooling Agent unit (over 500 metric tons per annum) and dedicated lines for Phenol and Citral derivatives, with MEHQ and Guaiacol production starting in Q4 FY26 (Jan/Feb).
Market Challenges and Mitigation Strategies
The company faced external challenges🌐 in Q2 FY26, including 50% US tariffs announced in August, which led to deferred export orders and lower volumes. Domestically, GST rate changes (Natural Mint to 5%, Synthetic to 18%) caused customers to reassess blend requirements and delay purchases in Mint and Clove categories. To mitigate these, management is strengthening sourcing, optimizing production, maintaining strict inventory discipline, and fast-tracking value-added products like BHA (now FY27 from FY28) to diversify revenue streams.
Product Portfolio, R&D, and Future Outlook
GEM Aromatics' portfolio includes specialty ingredients, essential oils, aroma chemicals, and value-added derivatives, with a strong focus on Phenol Derivatives, Cooling Agents, and Citral derivatives. The in-house R&D center, with 13 scientists, is crucial for developing new molecules and advancing green chemistry. The long-term demand outlook remains strong, supported by growth in Oral Care, Personal Care, Wellness, Flavors, Fragrances, and Alternative Medicine, with a target of ₹1,050-1,100 crores revenue and 16%-18% EBITDA margin by FY28.
Capital Structure and Debt Reduction
The company significantly strengthened its financial position by repaying ₹140 crores of debt in H1 FY26. This included ₹97.4 crores of long-term debt related to Krystal Ingredients and ₹42.6 crores of working capital borrowings. These repayments, utilizing IPO proceeds, improved the net debt to equity ratio to 0.3x from 0.8x, demonstrating a commitment to a healthier balance sheet.